[ad_1]
- Rhizen Pharma announces presentations at AACR showcasing its differentiated clinical stage PARP and DHODH programs
- Preclinical data on Rhizen’s differentiated PARP inhibitor RP12146, indicates a superior haematological safety profile that the company expects will translate through ongoing clinical trials.
- Preclinical data on Rhizen’s best-in-class DHODH inhibitor RP7214, indicates that it is active across AML models both as a single agent and in combination with SOC agents.
Rhizen Pharmaceuticals AG (Rhizen), a Switzerland-based privately held, clinical-stage oncology & inflammation-focussed biopharmaceutical company, announced the release of data on its differentiated next-generation clinical-stage PARP (Poly ADP-Ribose Polymerase) and DHODH ( DiHydro Orotate DeHydrogenase) inhibitor programs at the American Association for Cancer Research (AACR) 2022 Annual Meeting. Rhizen’s poster presentations describe the preclinical characterization and differentiated features of its novel PARP inhibitor (RP12146) and preclinical data supporting the broad positioning of its DHODH inhibitor ( RP7214) in AML.
Rhizen had earlier indicated that its PARP program had demonstrated differentiated IND enabling preclinical safety. The additional preclinical data being presented at AACR 2022 suggests that this differentiated safety may be due to the lower bone marrow distribution of RP12146 and concomitantly lower haematological toxicity. “We believe RP12146’s safety differential has allowed us to progress through the dose escalation study more efficiently. Further, the emerging data from our ongoing phase 1 dose escalation study is encouraging & corroborative with robust target engagement and safety observed so far. We believe that this differentiation, as it translates more fully in the clinic, may allow us to explore the full …
Full story available on Benzinga.com
[ad_2]
Source link
